Core Problem Statement

Exorbitant production costs, persistent import dependencies, and high logistical complexity render life-saving cell therapies completely inaccessible across emerging healthcare markets.

Solution Overview

A clinical-stage biopharma infrastructure enabling the end-to-end development of affordable, next-generation CAR-T cell therapies for cancer. It features a proprietary humanized anti-CD19 CAR-T construct alongside a validated vein-to-vein logistical supply chain across interconnected hospital networks.

Strategic Engagement Opportunities

ImmunoACT’s high-growth biotechnology model offers institutional healthcare providers, global clinical operators, and life science investors a scalable, domestically integrated clinical cell pipeline with structured expansion opportunities across regional markets.